In a recent study published in Cell, Kim et al. present a remotely controlled, electromagnetic field (EMF)-inducible gene switch, termed the Ei switch, that enables precise spatiotemporal activation of transgene expression in vivo without pharmacological agents or invasive procedures.1 By engineering a 450-bp EMF-responsive DNA element (Ei) derived from the leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) promoter, the authors established a transcriptional platform selectively responsive to extremely low-frequency EMF (EL-EMF) under the tested conditions, offering a non-invasive and reversible mode of gene regulation with the potential to address key limitations of optogenetics (limited tissue penetration) and reduce reliance on pharmacological inducers such as tetracycline-responsive systems.1,2,3Through an initial screening phase using single-cell RNA sequencing (scRNA-seq) of EMF-exposed mouse brains, followed by subsequent independent validation assays, Kim et al. identified Lgr4 as the most robustly and reproducibly upregulated gene across multiple cell types following EL-EMF exposure, characterized by rapid induction within 24 h and complete reversibility to basal transcript levels within 24 h of EMF withdrawal. Systematic deletion mapping of the Lgr4 promoter via luciferase reporter assays defined a minimal 450-bp upstream regulatory element designated the EMF-inducible DNA element (Ei) exhibiting maximal induction under optimal EMF parameters with negligible background transcriptional activity in the absence of EMF stimulation. To further improve kinetic precision, the authors engineered a second-generation enhanced Ei element (sEi) by fusing a cytomegalovirus (CMV) enhancer upstream of the Ei sequence, achieving robust transgene induction within 2 h of EMF exposure, thereby enabling temporally high-resolution gene control.A genome-wide pooled CRISPR-Cas9 knockout screen in Ei-GFP reporter fibroblasts, using a lentiviral sgRNA library targeting 20,611 genes, identified the membrane-bound electron carrier cytochrome b5 type B (Cyb5b) as an essential mediator of EMF-induced Ei activation. Individual knockout of Cyb5b completely abolished EMF-dependent reporter activation, while its reintroduction fully restored the response.Mechanistically, EMF exposure elicits rhythmic, sustained cytoplasmic Ca²⁺ oscillations that are distinct from the predominantly transient or non-oscillatory Ca²⁺ elevations induced by calcium ionophores or other pharmacological stimuli. These oscillations occur in a Cyb5b- and L-type voltage-gated calcium channel (VGCC; Cacna1f)-dependent manner, establishing a distinguishable, frequency-encoded Ca²⁺ signature. This oscillatory Ca²⁺ signature robustly activates the transcription factor Sp7, which undergoes EMF-dependent and reversible chromatin immunoprecipitation (ChIP)-confirmed binding to the Ei element, providing the mechanistic link between the physical EMF stimulus and transcriptional output via a Cyb5b → Cacna1f → Ca²⁺ oscillation → Sp7 → Ei signaling axis (Fig. 1a). Crucially, the discovery of Cyb5b represents a key conceptual advance, as it functions as an essential transducer that physically links macroscopic EMF stimuli to intracellular biochemical responses. Furthermore, the resulting EMF-induced rhythmic Ca²⁺ dynamics may function as a temporal code for bio-orthogonal transcriptome decoding, potentially contributing to transcriptional specificity under the tested conditions.Fig. 1Full size imageEMF → Cyb5b → Cacna1f → Ca²⁺ → Sp7 → Ei axis enables spatiotemporally precise gene control and diverse therapeutic applications. a Extremely low-frequency EMF activates membrane-bound Cyb5b, leading to L-type voltage-gated calcium channel (Cacna1f)-dependent rhythmic Ca²⁺ oscillations. This robustly activates Sp7, which binds to the 450-bp Ei element and initiates transcription. b Whole-body EMF exposure induces uniform transgene expression in multiple deep tissues, while a miniaturized EMF coil enables spatially restricted induction in selected anatomical regions. c Therapeutic applications of the EMF-inducible system include cyclic Oct4-Sox2-Klf4 (OSK) expression for mitigating aging, conditional APP induction for Alzheimer’s disease modeling, and circadian rhythm-tailored Tph2 induction in the dorsal raphe nucleus (DRN) for the treatment of depression. Figure created with BioRender.com (https://BioRender.com/ii9p3ro)Validated in transgenic Ei-GFP mice, the system demonstrated robust and coordinated transgene induction across multiple tissues, including the brain, heart, liver, spleen, kidney, and skin following whole-body EMF exposure, with rapid loss of transgene expression within approximately 3 days of EMF cessation, as assessed by GFP fluorescence. Precise spatial restriction was achieved using a miniaturized single-loop EMF coil (25 mm diameter), confining transgene induction predominantly to targeted anatomical regions (brain, thorax, abdomen, or pelvis), with minimized off-target induction in adjacent tissues, and Cre-dependent cell-type-restricted expression was demonstrated using Cre-dependent Ei-DIO (double-floxed inverse orientation) reporter vectors in Dat-Cre and Gfap-Cre transgenic mice (Fig. 1b).The therapeutic versatility of the Ei gene switch was demonstrated across three distinct biomedical contexts. First, cyclic EMF-driven expression of the partial reprogramming cassette Oct4-Sox2-Klf4 (OSK; 3 days ON/4 days OFF) in systemically transduced progeroid (LMNAG608G/G608G; 3-month-old) and naturally aged (20-month-old) mice significantly extended both median and maximal lifespans, improved physical appearance, reduced senescence-associated gene signatures, restored epigenetic marks (H3K9me3, H4K20me3, H3K4me3), and attenuated p16INK4a expression across multiple tissues without detectable induction of pluripotency markers such as Nanog or overt signs of hyperplasia under the tested conditions. This precise temporal control during in vivo partial reprogramming prevents the activation of endogenous pluripotency genes and subsequent hyperplasia, overcoming the inherent limitations of conventional transgenic models to establish a stringently regulated, non-invasive platform for in vivo application, suggesting that the combination of cyclic induction and precise temporal regulation could help mitigate risks historically associated with constitutive Oct4, Sox2, Klf4, and c-Myc (OSKM) expression.1,4 Second, conditional EMF-mediated induction of mutant amyloid precursor protein (APPNL-G-F) in aged Ei-APPNL-G-F transgenic mice reproduced age-dependent Aβ42/Aβ40 ratio increases, accelerated amyloid plaque deposition, neuroinflammation, and spatial-learning deficits, enabling inducible modeling of amyloid pathology in an age-dependent context. Importantly, this model demonstrates the ability to decouple intrinsic brain aging from pathogenic Aβ deposition, providing an advanced platform to accurately mimic the etiology of sporadic AD. Third, stereotaxic delivery of sEi-Tph2 to the dorsal raphe nucleus (DRN) of Tph2-R439H knock-in depression (80% depletion of serotonin) mice, combined with circadian-aligned 12 h cyclic EMF exposure, restored Tph2 mRNA levels, serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) concentrations in the examined brain regions, and rescued depressive- and anxiety-like behavioral phenotypes; notably, continuous 24 h EMF exposure failed to produce comparable behavioral improvement, indicating that temporal precision rather than cumulative transgene dose is critical for functional neuromodulation (Fig. 1c). Clarifying this temporal dependency, rhythmic Tph2 induction enables biomimetic regulation that mimics natural circadian oscillations, which is fundamentally required for behavioral rescue, as opposed to continuous expression.Despite its remarkable versatility, the Ei gene switch system has several limitations that must be addressed before clinical translation. The molecular mechanism by which EL-EMF physically modulates Cyb5b’s redox state and how this transduces to Cacna1f gating remain incompletely resolved, leaving an important mechanistic gap between the biophysical stimulus and the intracellular signaling cascade. All in vivo therapeutic validation was performed in small rodent models, and the translational scalability of the system particularly the ability of the miniaturized EMF coil to deliver spatially precise exposure at the anatomical dimensions of large animals or humans, has not been assessed; large-animal validation will be important prior to clinical testing. Furthermore, the Lgr4 Ei element exhibits tissue and cell-type-specific induction characteristics, and EMF-dependent gene activation efficiency has not been systematically benchmarked across all clinically relevant cell types. In the absence of AAV-based or other clinically approved delivery platforms being directly validated in this work, the choice of lentiviral delivery also raises potential insertional mutagenesis concerns for long-term therapeutic deployment. Lastly, long-term studies of device miniaturization, wearability, and dosimetric standardization across diverse biological contexts will be required to translate the system into practical clinical devices.The significance of this study extends well beyond the demonstration of a new inducible gene switch; it establishes EMF as a viable physical modality for non-invasive, remotely programmable gene regulation, with important implications for gene therapy, synthetic biology, regenerative medicine, and disease modeling. Unlike drug-based inducible systems that carry pharmacological liabilities or optogenetic approaches that are constrained by photon penetration depths of less than a few millimeters in tissue, EL-EMF is capable of penetrating deep tissues, is noninvasively deliverable through conventional electromagnetic devices, and can be spatially restricted using compact coil designs attributes that collectively point toward a potentially clinically translatable combination.1,2 The identification of Cyb5b as an essential EMF-responsive mediator, together with frequency-encoded Ca²⁺ oscillations, as a bio-orthogonal signaling mechanism under the tested conditions distinguishes the Ei switch from existing calcium-dependent gene circuits that are broadly responsive to diverse physiological stimuli, addressing a key concern about induction specificity in vivo. The OSK partial reprogramming application provides a potential strategy to address a central translational challenge in the field the balance between rejuvenation efficacy and oncogenic risk by providing a precision dosing mechanism that is difficult to achieve with constitutive or stochastically regulated expression systems.1,4 Similarly, the EMF-inducible APP model wherein pathological Aβ accumulation is decoupled from the confounding effects of constitutive transgene expression on normal brain development represents a conceptually distinct and potentially advantageous platform for dissecting disease mechanisms and evaluating therapeutic candidates in an age-stratified context. Collectively, the Ei gene switch represents a promising platform for remote gene control, with the potential to broadly accelerate the development of next-generation cell and gene therapies, programmable disease models, and spatiotemporally controlled regenerative interventions across areas such as neurodegeneration, depression, aging, and disease modeling.ReferencesKim, J. et al. Electromagnetic field-inducible in vivo gene switch for remote spatiotemporal control of gene expression. Cell 189, 3465–3480.e23 (2026).Article CAS PubMed Google Scholar Chen, S. et al. Near-infrared deep brain stimulation via upconversion nanoparticle-mediated optogenetics. Science 359, 679–684 (2018).Article CAS PubMed Google Scholar Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547–5551 (1992).Article CAS PubMed PubMed Central Google Scholar Ocampo, A. et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell 167, 1719–1733 e1712 (2016).Article CAS PubMed PubMed Central Google Scholar Download referencesAcknowledgementsThis research was supported by the KRIBB Research Initiative Program (KQM0042611), National Research Foundation (NRF) funded by the Korean government (MSIT) (RS-2021NR057659, RS-2025-00518480, RS-2026-25476968), and the National Research Council of Science & Technology (NST) grant by the Korea government (MSIT) (No. GTL24023-000) and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (RS-2026-25502637).Author informationAuthors and AffiliationsFuturistic Animal Resource and Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of KoreaHae-Jun Yang & Young-Ho ParkDepartment of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of KoreaMinYoung KimAdvanced Bioconvergence Department, KRIBB School, Korea National University of Science and Technology (UST), Daejeon, Republic of KoreaYoung-Ho ParkAuthorsHae-Jun YangView author publicationsSearch author on:PubMed Google ScholarMinYoung KimView author publicationsSearch author on:PubMed Google ScholarYoung-Ho ParkView author publicationsSearch author on:PubMed Google ScholarContributionsH.J.Y., M.K. and Y.H.P. designed, researched, and wrote the manuscript. All authors have read and agreed to the final version of the manuscript.Corresponding authorsCorrespondence to Hae-Jun Yang, MinYoung Kim or Young-Ho Park.Ethics declarationsCompeting interestsThe authors declare no competing interests.Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Rights and permissionsOpen Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.Reprints and permissionsAbout this article